Viral Hemorrhagic Fever Overview

Save information for later
Sign Up

Learn About Viral Hemorrhagic Fever

What is the definition of Viral Hemorrhagic Fever?
Viral hemorrhagic fevers is a term used to describe a group of illnesses caused by four different families of viruses that severely affect multiple body systems. Some of the more commonly known types of viral hemorrhagic fevers include Ebola virus, Lassa fever, Hantavirus, Tick-borne encephalitis, and Rift Valley fever. Viral hemorrhagic fevers are carried by insects, rats, and mice and are limited to specific geographical areas in which the insects and animals live, such as West Africa (Lassa fever). While humans can be infected by contact with an infected insect or animal, these viruses can also be transmitted from one human to another and are highly contagious.
What are the symptoms of Viral Hemorrhagic Fever?
While certain types of viral hemorrhagic fevers may cause only mild illness, many of these can cause severe, life-threatening symptoms, and even death. Symptoms may also include muscle aches, extreme fatigue, and high fever. An infected person’s vascular system is often damaged, while the body loses ability to regulate. Vascular damage causes hemorrhage (bleeding).
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Viral Hemorrhagic Fever?
Most viral hemorrhagic diseases have no treatment. However, the antiviral drug, ribavirin, may help to shorten the course of illness, and, in some cases, may even prevent infection. Patients are mainly treated with supportive care, which includes prevention of dehydration. Some patients may need kidney dialysis in the event of kidney failure.
Who are the top Viral Hemorrhagic Fever Local Doctors?
Dr. John M. Powers
Family Medicine
Dr. John M. Powers
Family Medicine

Warren Clinic Inc

101 Rockefeller Dr, Suite 203, 
Muskogee, OK 
 116.5 mi
Accepting New Patients
Offers Telehealth
Languages Spoken English

John Powers is a Family Medicine provider in Muskogee, Oklahoma. Dr. Powers and is rated as an Experienced provider by MediFind in the treatment of Viral Hemorrhagic Fever. His top areas of expertise are Togaviridae Disease, Chikungunya, Severe Acute Respiratory Syndrome (SARS), and Flu. Dr. Powers is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
View All Doctors
What are the latest Viral Hemorrhagic Fever Clinical Trials?
A Cluster-Randomized Trial to Evaluate the Efficacy of Wolbachia-Infected Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil
A Cluster-Randomized Trial to Evaluate the Efficacy of Wolbachia-Infected Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil
Enrollment Status: Recruiting
Publish Date: December 27, 2024
Intervention Type: Other
Study Phase: Not Applicable

Summary: This is a cluster randomized controlled trial (CRCT) to evaluate the efficacy of Wolbachia-infected A. aegypti mosquito releases in reducing the burden of ARBV infection in Brazil over four years. The intervention will be the release of Wolbachia-infected A. aegypti mosquitoes. Standard control measures routinely established by the Belo Horizonte City Hall as recommended by the PNCD, will continue...

Match to trials
Find the right clinical trials for you in under a minute
Get started
The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever: A Double-blind, Randomized Control Trial
The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever: A Double-blind, Randomized Control Trial
Enrollment Status: Recruiting
Publish Date: December 20, 2024
Intervention Type: Other, Drug
Study Phase: Phase 3

Summary: This study investigates the comparative efficacy of standard treatment plus Ribavirin versus standard treatment alone in preventing clinically significant hemorrhage among patients diagnosed with dengue fever. It is a double-blind, randomized control trial aimed at determining whether the addition of Ribavirin improves clinical outcomes, particularly reducing bleeding events.

View All Clinical Trials